

**STRIDES PHARMA CANADA INC.**  
**BALANCE SHEET AS AT MARCH 31, 2020**

		Amount in CAD	Amount in CAD
		31-Mar-20	31-Mar-19
<b>A</b>	<b>ASSETS</b>		
<b>I</b>	<b>Non-current assets</b>		
	(a) Property, plant and equipment	1,130	350
	(b) Intangibles assets under development	1,77,330	-
	(c) Financial assets		
	(i) Investments	38,03,196	38,03,195
	<b>Total non-current assets</b>	<b>39,81,656</b>	<b>38,03,545</b>
<b>I</b>	<b>Current assets</b>		
	(a) Financial assets		
	(i) Trade receivables	3,222	2,42,847
	(ii) Cash and cash equivalents	44,844	43,078
	(iii) Other financial assets	-	151
	(b) Other current assets	18,55,441	28,282
	<b>Total current assets</b>	<b>19,03,507</b>	<b>3,14,359</b>
	<b>TOTAL ASSETS</b>	<b>58,85,163</b>	<b>41,17,903</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>I</b>	<b>Equity</b>		
	(a) Equity share capital	1,000	1,000
	(b) Other equity	51,72,303	37,26,157
	<b>Total Equity</b>	<b>51,73,303</b>	<b>37,27,157</b>
<b>II</b>	<b>Liabilities</b>		
<b>1</b>	<b>Current liabilities</b>		
	(a) Financial liabilities		
	(i) Trade payables	7,11,860	3,90,746
	<b>Total current liabilities</b>	<b>7,11,860</b>	<b>3,90,746</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>58,85,163</b>	<b>41,17,904</b>

**STRIDES PHARMA CANADA INC.**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2020**

	Particulars	Note No.	Amount in CAD	Amount in CAD
			31-Mar-20	31-Mar-19
1	Revenue from operations	9	1,36,500	2,42,847
2	Other Income		4,132	-
3	<b>Total Revenue (1+2)</b>		<b>1,40,632</b>	<b>2,42,847</b>
4	<b>Expenses</b>			
	(a) Purchases of stock in trade		-	1,81,980
	(b ) Employee benefits expense	10	2,11,593	1,932
	(c) Finance costs	11	1,627	317
	(d ) Depreciation and amortisation expense		77	175
	(e) Other expenses	12	2,97,081	2,89,843
	<b>Total expenses</b>		<b>5,10,378</b>	<b>4,74,247</b>
5	<b>Profit / (Loss) before exceptional items and taxes (3-4)</b>		<b>(3,69,746)</b>	<b>(2,31,400)</b>
6	Exceptional Item		73,289	(2,43,500)
7	<b>Profit / (Loss) before taxes (5+6)</b>		<b>(4,43,035)</b>	<b>(4,74,900)</b>
8	<b>Tax Expense:</b>			
	(1) Current tax		-	-
	(2) Deferred tax		-	-
	Total tax expenses		-	-
9	<b>Profit / (Loss) for the year after tax</b>		<b>(4,43,035)</b>	<b>(4,74,900)</b>

STRIDES PHARMA CANADA INC.  
STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED MARCH 31, 2020

(A) Equity share capital

Particulars	Amount in CAD
Balance as at March 31, 2018	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2019	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2020	1,000

(B) Other equity

Particulars	Share application money pending allotment	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2018	-	(22,026)	-	(22,025.95)
Application money received during the year	42,23,084	-	-	42,23,084
Profit/loss for the year	-	(4,74,900)	-	(4,74,900)
Balance as at March 31, 2019	42,23,084	(4,96,926)	-	37,26,157
Application money received during the year	18,89,181	-	-	18,89,181
Profit/loss for the year	-	(4,43,035)	-	(4,43,035)
Balance as at March 31, 2020	61,12,265	(9,39,962)	-	51,72,303

STRIDES PHARMA CANADA INC.  
Notes forming part of financial statement

Note

No.

1 Non current investments		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Pharmapar Inc	38,03,196	38,03,195	
<b>Total</b>	<b>38,03,196</b>	<b>38,03,195</b>	

  

2 Trade receivables		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
<b>Unsecured</b>			
Considered good	3,222	2,42,847	
Considered doubtful	-		
	3,222	2,42,847	
Less: Allowance for doubtful trade receivables	-		
<b>Total</b>	<b>3,222</b>	<b>2,42,847</b>	

  

3 Cash and cash equivalents		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Cash in hand			
Balances with banks:			
In current accounts	44,844	43,078	
<b>Total</b>	<b>44,844</b>	<b>43,078</b>	

  

4 Other financial assets		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Advances to related parties	-	151	
<b>Total</b>	<b>-</b>	<b>151</b>	

  

5 Other current assets		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
<b>Unsecured, considered good</b>			
Loans and advances to Group entities	18,28,346	-	
Balances with government authorities:	27,095	28,282	
<b>Total</b>	<b>18,55,441</b>	<b>28,282</b>	

  

6 Share capital		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
<b>Issued, subscribed and fully paid-up</b>			
Equity share capital	1,000	1,000	
<b>Total</b>	<b>1,000</b>	<b>1,000</b>	

  

7 Reserves and surplus		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Share Application money Pending Allotment	61,12,265	42,23,084	
	<b>61,12,265</b>	<b>42,23,084</b>	
<b>Surplus in statement of profit and loss</b>			
Opening balance	(4,96,926)	(22,026)	
Add: Profit / (Loss) for the year	(4,43,035)	(4,74,900)	
Closing balance	<b>(9,39,962)</b>	<b>(4,96,926)</b>	
<b>Total</b>	<b>51,72,303</b>	<b>37,26,157</b>	

  

8 Trade payables		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Trade payable	7,11,860	3,90,746	
<b>Total</b>	<b>7,11,860</b>	<b>3,90,746</b>	

STRIDES PHARMA CANADA INC.  
Notes forming part of financial statement

Note

No.

9 Revenue from operations		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Sale of Product	1,36,500	2,42,847	
<b>Total</b>	<b>1,36,500</b>	<b>2,42,847</b>	

10 Employee Benefit Expenses		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Salaries and wages	2,11,593	-	
Staff Welfare	-	1,932	
<b>Total</b>	<b>2,11,593</b>	<b>1,932</b>	

11 Finance cost		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Other finance Cost	1,627	317	
<b>Total</b>	<b>1,627</b>	<b>317</b>	

12 Other expenses		Amount in CAD	
Particulars	31-Mar-20	31-Mar-19	
Sundry Balance of Written back	407	-	
Director sitting fees	20,000	-	
Rates & Taxes	1,12,417	71,529	
Insurance	4,056	-	
Printing & Stationery	-	307	
Conveyance & Travelling	21,275	-	
Communication expenses	-	1,308	
Net loss on foreign currency transactions	40,516	676	
Professional fees	98,411	2,16,023	
<b>Total</b>	<b>2,97,081</b>	<b>2,89,843</b>	